FOXO3 and achalasia-alacrima syndrome: After 28 days of Ang II infusion, there was a substantial increase in AAA formation in the AAV-FoxO3a group (11 of 30 mice (36.6%) in the AAV-FoxO3a group developed AAAs; p < 0.05; Fig. 4A, B) compared with the AAV-GFP group, in which AAA formation was nearly absent (3 of 30 mice (10%) in the AAV-GFP group developed AAAs; p < 0.05; Fig. 4A, B).